Huntleigh Advisors Inc. Has $2.97 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Huntleigh Advisors Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 2.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,542 shares of the medical research company’s stock after buying an additional 184 shares during the quarter. Huntleigh Advisors Inc.’s holdings in Amgen were worth $2,973,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. First Pacific Financial raised its stake in Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock worth $28,000 after acquiring an additional 67 shares in the last quarter. Pinney & Scofield Inc. bought a new position in Amgen in the 4th quarter valued at approximately $26,000. Ritter Daniher Financial Advisory LLC DE lifted its stake in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new stake in Amgen in the fourth quarter valued at approximately $34,000. Finally, Atala Financial Inc bought a new stake in shares of Amgen during the fourth quarter worth $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.76% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $298.25 on Friday. The stock has a market capitalization of $160.37 billion, a price-to-earnings ratio of 27.21, a PEG ratio of 2.68 and a beta of 0.49. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. The stock’s 50 day moving average price is $282.12 and its two-hundred day moving average price is $286.57.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.96 EPS. On average, equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. Erste Group Bank cut Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Guggenheim started coverage on Amgen in a report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 target price for the company. UBS Group reaffirmed a “neutral” rating and issued a $315.00 price objective (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Royal Bank Of Canada cut their target price on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Finally, Morgan Stanley restated an “equal weight” rating on shares of Amgen in a research report on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $307.82.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.